Stereotaxis Reports Q4 Revenue Growth Amid Continued R&D Investment

Stereotaxis Inc. (STX) posted Q4 revenue of $14.3 million, marking a 12% increase compared to $12.8 million in the same period the prior year. The growth was primarily attributed to the activation of five new robotic ablation systems in Europe and Asia, with international revenue accounting for 63% of total sales. Despite the revenue uptick, the company reported a net loss of $5.2 million, widening from $3.9 million in Q4 2024, due to a $2.1 million increase in research and development expenditures. The company highlighted progress in regulatory milestones, including the submission of a pre-market approval (PMA) supplement to the FDA for its latest generation of magnetic navigation systems. Stereotaxis also announced a strategic partnership with a regional healthcare provider in Germany to deploy its technology across three cardiac centers, a move expected to drive future revenue visibility. During the earnings call, management reiterated its long-term goal of achieving non-GAAP profitability by 2027. Shares of STX closed at $4.87 on March 8, 2026, reflecting a 7% decline over the past month amid broader healthcare sector volatility. The stock remains under the $5 threshold, a level that has historically served as a psychological barrier for investors in small-cap medical device firms. Meanwhile, the broader healthcare sector, as measured by the XLV ETF, saw a 1.3% gain during the same period, while IHI (IHI Corporation) posted a 2.4% increase, indicating sector-specific momentum in Japanese industrial healthcare providers.